We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Adult Stem Cells Can Also Self-Renew

By Biotechdaily staff writers
Posted on 11 Jul 2005
In a ground-breaking study, scientists have discovered that adult, or post-natal, stem cells have the same ability as embryonic stem cells to multiply, which was not previously known.

Embryonic stem cells are often favored over adult or post-natal stem cells because it was generally believed that embryonic stem cells had a greater capacity to multiply than post-natal stem cells, making them more desirable to research as a potential treatment. More...


"Scientists have typically believed that adult or post-natal stem cells grow old and die much sooner than embryonic stem cells, but this study demonstrates that is not the case,” said senior author Dr. Johnny Huard, Ph.D., director of the Growth and Development Laboratory at Children's Hospital of Pittsburgh (PA, USA).

Researchers in Dr. Huard's laboratory were able to expand post-natal stem cells to a population level comparable to that reached by researchers using embryonic stem cells. Prior research showed that embryonic stem cells could undergo more than 200 population doublings before the cells begin to die. The researchers discovered that a unique population of muscle-derived stem cells was able to undergo more than 200 population doublings as well while keeping the ability to regenerate muscle in an animal model, a finding indicating that they could maintain their treatment potential. The study findings were reported in the July 1, 2005, issue of Molecular Biology of the Cell.

In addition to avoiding the current debate about the research use of embryonic stem cells, the use of post-natal cells could offer another important advantage: autoimmunity. With post-natal stem cells taken from the recipient and then reintroduced in an autologous manner, rejection would not be an issue.





Related Links:
Children's Hospital of Pittsburgh

New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Gold Member
Aspiration System
VACUSAFE
New
Manual Pipetting Aid
Pipette Controllers macro
New
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.